Kinaxis Appoints Razat Gaurav as New CEO
Kinaxis® Inc. (TSX:KXS), a global leader in supply chain orchestration, today announced the appointment of Razat Gaurav as Chief Executive Officer (CEO) effective January 12, 2026, his official start date, at which time he will also join the Kinaxis Board of Directors.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260108330975/en/
Razat Gaurav, Kinaxis CEO
“After a rigorous search, the Board selected Razat to lead the company as CEO,” said Bob Courteau, Interim CEO and Board Chair at Kinaxis. “Razat’s twenty-five years of experience in supply chain solutions, his proven track record in advancing innovation-driven growth, and his passion for developing high-performing cultures make him uniquely qualified for this role. The Board looks forward to supporting Razat as he leads Kinaxis to the next phase of growth and success.”
Gaurav has an established track record of building and scaling global organizations in high-growth markets. He was the former CEO of both Planview and LLamasoft and previously held senior roles at Blue Yonder and i2 Technologies. He is also a board member at SPS Commerce, a publicly traded SaaS company helping businesses exchange data, automate processes, and run more efficient supply chains.
Since becoming CEO of Planview in 2021, Gaurav transformed the company’s AI journey, anchoring its mission to build the digital future of connected work. Under his leadership, Planview launched an enterprise-grade next-generation AI platform designed to harness the power of the latest emerging data architectures and multi-agent AI capabilities. This led to Planview more than doubling its revenue while maintaining high operating margins during his tenure.
"I’m excited to join the Kinaxis team and return to my roots in supply chain,” said Razat Gaurav, Chief Executive Officer. “Kinaxis is uniquely positioned to redefine the future of intelligent supply chains. Building on its rich legacy of concurrent planning, I will champion the next generation of AI-driven decision making and supply chain orchestration, using the Maestro platform. I appreciate the Board’s confidence and pledge to lead the company in setting new standards for innovation, building lasting partnerships and creating value for employees, customers and shareholders.”
This planned leadership transition reinforces Kinaxis’s commitment to creating sustainable long-term value for employees, customers, and shareholders. With this appointment, and other key leadership additions including Mark Morgan, President of Global Commercial, the executive team at Kinaxis is built to deliver sustained growth and lead the transformation of global supply chains.
Bob Courteau, Interim CEO, will now return to his role as non-executive Board Chair of Kinaxis. Given Courteau’s recent tenure in an executive role, Angel Mendez will continue as Independent Lead Director.
About Kinaxis
Kinaxis is a leader in modern supply chain orchestration, powering complex global supply chains, and supporting the people who manage them. Our powerful, AI-infused supply chain orchestration platform, Maestro, combines proprietary technologies and techniques that provide full transparency and agility across the entire supply chain — from multi-year strategic planning to last-mile delivery. We are trusted by renowned global brands to provide the agility and predictability needed to navigate today’s volatility and disruption. For more news and information, please visit kinaxis.com or follow us on LinkedIn.
Cautionary Note and Forward-Looking Information
This news release contains forward-looking information within the meaning of Canadian securities legislation. Forward-looking information relates to future events or anticipated performance. This information is provided to help readers understand management’s beliefs, expectations, and opinions as at the date of this release and may not be suitable for other purposes. Forward-looking information in this news release includes statements regarding Kinaxis’ plans and prospects for growth, expansion, and innovation. Kinaxis’ actual performance may be materially different.
Forward-looking information is subject to a variety of risks and uncertainties which could cause actual events or results to differ including, without limitation, the risks described under the heading “Risk Factors” in the Company’s annual information form dated February 26, 2025 for its fiscal year ended December 31, 2024 and other risks identified in the Company’s filings with Canadian securities regulators available on SEDAR+ at https://www.sedarplus.ca. These risk factors are not exhaustive. The Company does not assume any obligation to update forward-looking information, other than as required by applicable law. For the reasons set forth above, one should not place undue reliance on forward-looking information.
Source: Kinaxis Inc
View source version on businesswire.com: https://www.businesswire.com/news/home/20260108330975/en/
Contacts
Media Relations
Matt Tatham | Kinaxis
mtatham@kinaxis.com
+1 917-446-7227
Investor Relations
Rick Wadsworth | Kinaxis
rwadsworth@kinaxis.com
+1 613-907-7613
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
www.businesswire.com

Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Biocytogen and Acepodia Expand Collaboration Through Option-based Evaluation Framework for First-in-Class Bispecific and Dual-Payload ADCs (BsAD2C)9.1.2026 14:00:00 EET | Press release
Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (Biocytogen, SSE: 688796; HKEX: 02315) and Acepodia (6976:TT), today announced that the companies have entered into an option and license agreement designed to enable the structured evaluation of bispecific antibody-drug conjugate (BsADC) programs to further advance the development of dual-payload bispecific antibody-drug conjugates (BsAD2Cs). The agreement grants Acepodia an option to obtain an exclusive worldwide license from Biocytogen for two BsADC programs. Under the terms of the agreement, Biocytogen is eligible to receive an upfront option fee and, upon Acepodia’s exercise of the option, additional payments including option exercise fees, development, regulatory, and commercial milestone payments, as well as royalties on future product sales. The financial terms of the agreement were not disclosed. “This new agreement builds upon our recent co-development collaboration with Acepodia, which has focused on the evaluation and selection
Blockstream Capital Partners Announces Strategic Acquisition of Derivatives Trading Team from Numeus Group, Leveraging Strategic Partnership with Komainu9.1.2026 12:08:00 EET | Press release
Blockstream Capital Partners (“BCP”) today announced that it has entered into a strategic agreement to acquire a division within Numeus Group’s digital asset trading and investment business. The transaction includes the absorption of select Bitcoin focused trading strategies with a focus on yield generation as well as a ten person derivatives trading team led by Chief Investment Officer Deepak Gulati, a specialist in volatility and derivatives markets. Deepak Gulati, appointed Co-Chief Investment Officer of Blockstream Capital Management alongside Rodrigo Rodriguez, previously served as Global Head of Proprietary Trading at JPMorgan, before founding Argentiere Capital, a multibillion-dollar volatility-focused hedge fund. With a thesis that derivatives would drive Bitcoin and digital asset market maturity, he co-founded Numeus Group in 2021 to develop institutional-grade trading, risk management and market-structure capabilities. Komainu, an existing BCP strategic investment, has played
Autel Unveils Strategic Shift at CES 2026: Building the AI-Powered Infrastructure of Future Cities9.1.2026 11:44:00 EET | Press release
At the Consumer Electronics Show (CES), Autel Energy is presenting its latest AI-driven smart hardware and software systems for the future of intelligent urban operations. This year’s showcase highlights Autel’s shift from AI concept validation to scenario-based engineering deployment, emphasizing closed-loop execution across real-world infrastructure. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260101511436/en/ Autel Energy New Product Debut at CES 2026 Focusing on two key domains — Smart Energy and Smart Inspection — the company is unveiling a range of new products. In Smart Energy, Autel is introducing V2G (Vehicle-to-Grid) AC charger for homes and DC charging solution for fleets, strengthening its multi-tier energy touchpoint strategy from households to commercial operations. Live demonstrations at the booth will feature a smart charging robot showcasing automated plug-in capabilities. In Smart Inspection, Autel will
Allianz and Anthropic Forge Global Partnership to Advance Responsible AI in Insurance9.1.2026 11:00:00 EET | Press release
Allianz SE and Anthropic today announced a global partnership to accelerate the adoption of responsible Artificial Intelligence (AI) at Allianz. The collaboration centers on three transformative projects within Allianz Group designed to empower Allianz employees and accelerate operations, while setting new benchmarks for accuracy. “With this partnership, Allianz is taking a decisive step to address critical AI challenges in insurance. Anthropic’s focus on safety and transparency complements our strong dedication to customer excellence and stakeholder trust. Together, we are building solutions that prioritize what matters most to our customers while setting new standards for innovation and resilience,” said Oliver Bäte, CEO of Allianz SE. “Insurance is an industry where the stakes of using AI are particularly high: the decisions can affect millions of people. Allianz and Anthropic both take that very seriously, and we look forward to working together to make insurance better for those w
MRM Health Secures FDA IND Clearance to Launch its Phase 2b Trial of MH002 in Mild-to-Moderate Ulcerative Colitis9.1.2026 08:00:00 EET | Press release
MRM Health NV, a clinical-stage biopharmaceutical company pioneering microbiome-based therapeutics for inflammatory diseases and immune-oncology, today announced that the U.S. Food and Drug Administration (FDA) has granted clearance of its Investigational New Drug (IND) application for its lead program MH002. This enables the initiation of the STARFISH-UC Phase 2b clinical trial in patients with mild-to-moderate ulcerative colitis, marking a significant step forward in the development of next-generation therapies for inflammatory bowel diseases (IBD). About the STARFISH-UC Phase 2b Trial The STARFISH-UC trial is a randomized, double-blind, placebo-controlled study designed to confirm the promising efficacy signals and favorable safety profile previously observed in MH002’s Phase 2a studies. MH002, a rationally designed live microbial consortium, is the most advanced Live Biotherapeutic Product (LBP) of its kind, targeting disease-specific mechanisms through a synergistic combination of
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom